| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGLV3-25 |
| Uniprot No | P01717 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 氨基酸序列 | MAWIPLLLPLLTLCTGSEASYELTQPPSVSVSPGQTARITCSADALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADTSGTYVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
| 分子量 | 51.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGLV3-25蛋白的参考文献示例，基于该蛋白在疾病研究和抗体工程领域的潜在应用进行概括(注：以下为模拟示例，实际文献需通过学术数据库核实)：
---
1. **文献名称**：*Autoantibody profiling in systemic lupus erythematosus reveals IGLV3-25-associated epitopes*
**作者**：Zhang L, et al.
**摘要**：本研究分析了系统性红斑狼疮(SLE)患者血清中的自身抗体，发现IGLV3-25基因编码的轻链可变区与抗核抗体特异性结合。通过重组表达人IGLV3-25蛋白，证实其在体外可与DNA-组蛋白复合物相互作用，提示其在SLE发病机制中的潜在作用。
---
2. **文献名称**：*Recombinant expression and structural characterization of the IGLV3-25 protein in E. coli*
**作者**：Smith JR, et al.
**摘要**：报道了在大肠杆菌中高效表达重组人IGLV3-25蛋白的方法。通过X射线晶体学解析其三维结构，揭示了该轻链可变区的独特构象，为抗体工程中的稳定性优化提供了结构基础。
---
3. **文献名称**：*IGLV3-25 as a novel biomarker in B-cell malignancies*
**作者**：Wang H, et al.
**摘要**：研究发现B细胞淋巴瘤中IGLV3-25基因异常高表达。重组表达的IGLV3-25蛋白被用于开发诊断试剂，可特异性识别患者样本中的恶性B细胞，为肿瘤靶向治疗提供新策略。
---
4. **文献名称**：*Engineering single-chain antibodies using IGLV3-25 for CAR-T cell therapy*
**作者**：Garcia M, et al.
**摘要**：利用重组IGLV3-25蛋白构建单链抗体片段(scFv)，并整合到CAR-T细胞中。实验显示，该设计增强了CAR-T对特定肿瘤抗原的识别能力，为个性化免疫治疗提供了新思路。
---
**提示**：实际研究中建议通过PubMed或Google Scholar以关键词“IGLV3-25”“recombinant antibody light chain”等检索最新文献，或结合具体研究领域(如自身免疫病、肿瘤免疫)进行针对性查询。
Recombinant human IGLV3-25 protein is a synthesized form of the immunoglobulin lambda variable 3-25 (IGLV3-25) chain, a component of antibody molecules. Encoded by the IGLV3-25 gene located on chromosome 22q11.2. this protein contributes to the variable (V) domain of immunoglobulin lambda light chains, which pair with heavy chains to form antigen-binding regions in antibodies. The lambda light chains, including IGLV3-25. are critical for antibody diversity and antigen recognition, influencing immune responses.
Recombinant production typically involves cloning the IGLV3-25 gene sequence into expression systems (e.g., bacterial, mammalian, or insect cells) to generate purified protein for research. Structurally, it retains conserved framework regions (FRs) and complementarity-determining regions (CDRs) necessary for antigen interaction. Researchers use recombinant IGLV3-25 to study B-cell receptor specificity, antibody-antigen interactions, and molecular mechanisms in immune disorders. It also aids in developing therapeutic antibodies or biomarkers for diseases like cancers, autoimmune conditions, or infections, where lambda chain diversity is relevant.
Dysregulation of IGLV3-25 expression has been noted in certain B-cell malignancies, suggesting its potential role in oncogenesis. The recombinant protein enables functional studies to explore these associations. By providing a controlled, high-purity antigenic template, it supports structural biology (e.g., crystallography) and drug discovery. Its use underscores the importance of lambda light chains in adaptive immunity and targeted therapy design.
×
